Charles E. de Bock

3.4k total citations
69 papers, 2.0k citations indexed

About

Charles E. de Bock is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Charles E. de Bock has authored 69 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 14 papers in Public Health, Environmental and Occupational Health and 14 papers in Hematology. Recurrent topics in Charles E. de Bock's work include Acute Lymphoblastic Leukemia research (14 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Charles E. de Bock is often cited by papers focused on Acute Lymphoblastic Leukemia research (14 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Charles E. de Bock collaborates with scholars based in Australia, Belgium and United States. Charles E. de Bock's co-authors include Rick F. Thorne, Yao Wang, Xu Dong Zhang, Jan Cools, Elham Sadeqzadeh, Sofie Demeyer, Peter Hersey, Ellen Geerdens, Olga Gielen and Timothy J. Molloy and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Charles E. de Bock

65 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles E. de Bock Australia 26 1.1k 433 432 286 284 69 2.0k
Steven Goossens Belgium 26 1.9k 1.7× 649 1.5× 805 1.9× 409 1.4× 356 1.3× 71 3.0k
Rodrigo Jácamo United States 27 1.2k 1.0× 402 0.9× 466 1.1× 361 1.3× 197 0.7× 66 2.2k
Diana Bellavia Italy 30 1.9k 1.6× 564 1.3× 636 1.5× 850 3.0× 157 0.6× 57 3.0k
Jesús Pérez‐Losada Spain 27 1.6k 1.4× 496 1.1× 1.1k 2.6× 254 0.9× 348 1.2× 71 2.7k
Juan Carlos Rodríguez‐Manzaneque Spain 22 1.2k 1.0× 790 1.8× 460 1.1× 319 1.1× 396 1.4× 40 2.4k
Deniz Toksoz United States 30 1.8k 1.5× 204 0.5× 459 1.1× 458 1.6× 432 1.5× 49 2.9k
Shravan K. Chintala United States 27 1.0k 0.9× 766 1.8× 426 1.0× 121 0.4× 290 1.0× 57 2.3k
Misao Ohki Japan 19 2.3k 2.0× 299 0.7× 365 0.8× 246 0.9× 134 0.5× 26 2.9k
Luke B. Hesson Australia 29 2.4k 2.1× 494 1.1× 402 0.9× 173 0.6× 487 1.7× 66 3.0k
D. Wade Clapp United States 23 1.4k 1.2× 229 0.5× 335 0.8× 282 1.0× 243 0.9× 36 2.1k

Countries citing papers authored by Charles E. de Bock

Since Specialization
Citations

This map shows the geographic impact of Charles E. de Bock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles E. de Bock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles E. de Bock more than expected).

Fields of papers citing papers by Charles E. de Bock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles E. de Bock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles E. de Bock. The network helps show where Charles E. de Bock may publish in the future.

Co-authorship network of co-authors of Charles E. de Bock

This figure shows the co-authorship network connecting the top 25 collaborators of Charles E. de Bock. A scholar is included among the top collaborators of Charles E. de Bock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles E. de Bock. Charles E. de Bock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bond, Danielle R., B. M. R. Harvey, Luiza Steffens Reinhardt, et al.. (2025). Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal. Leukemia. 39(9). 2275–2280.
2.
Demeyer, Sofie, Nicole Mentens, Kris Jacobs, et al.. (2025). TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia. Leukemia. 39(3). 568–576. 1 indexed citations
3.
Zhang, Yuanyuan, Yang Yu, Xiaoying Liu, et al.. (2025). FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome. International Journal of Biological Sciences. 21(5). 2201–2222.
4.
Bock, Charles E. de, et al.. (2024). Less is more: Depleting myeloid‐biased HSCs to restore immune function. HemaSphere. 8(7). e125–e125.
5.
Evans, Kathryn L., Christopher M. Smith, Eric J. Earley, et al.. (2024). In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts. Experimental Hematology. 132. 104176–104176.
6.
Zhang, Qing, Yingying Wang, Pan Zhao, et al.. (2024). The tumor suppressor Fat1 is dispensable for normal murine hematopoiesis. Journal of Leukocyte Biology. 116(4). 909–914. 1 indexed citations
7.
Lin, Haiyan, Yizhou Huang, Charles E. de Bock, et al.. (2023). 3D bioprinted alginate-gelatin hydrogel patches containing cardiac spheroids recover heart function in a mouse model of myocardial infarction. Bioprinting. 30. e00263–e00263. 18 indexed citations
8.
Heatley, Susan L., Laura N Eadie, Barbara J. McClure, et al.. (2021). HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene. 41(6). 797–808. 14 indexed citations
9.
Verbeke, Delphine, Sofie Demeyer, Cristina Prieto, et al.. (2020). The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. Clinical Cancer Research. 26(21). 5747–5758. 21 indexed citations
10.
Connerty, Patrick, Richard B. Lock, & Charles E. de Bock. (2020). Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer. Frontiers in Oncology. 10. 285–285. 40 indexed citations
11.
Broux, Michaël, Cristina Prieto, Sofie Demeyer, et al.. (2019). Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. Blood. 134(16). 1323–1336. 33 indexed citations
12.
Bock, Charles E. de, Sofie Demeyer, Sandrine Degryse, et al.. (2018). HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discovery. 8(5). 616–631. 70 indexed citations
13.
Vicente, Carmen, Sofie Demeyer, Charles E. de Bock, et al.. (2018). The CCR4-NOT complex is a tumor suppressor in Drosophila melanogaster eye cancer models. Journal of Hematology & Oncology. 11(1). 108–108. 13 indexed citations
14.
Pajic, Marina, Danielle Froio, Sheridan Daly, et al.. (2017). miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense. Cancer Research. 78(2). 501–515. 110 indexed citations
15.
Dagklis, Antonis, Sofie Demeyer, Jolien De Bie, et al.. (2016). Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors. Blood. 128(23). 2642–2654. 40 indexed citations
16.
Bie, Jolien De, Antonis Dagklis, Sofie Demeyer, et al.. (2016). HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PREDICTS RESPONSE TO SMO AND GLI1 INHIBITORS. Haematologica. 101. 26–26. 1 indexed citations
17.
Jiang, Chen Chen, Kelly A. Avery‐Kiejda, Margaret Wade, et al.. (2008). Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress. Cancer Research. 68(16). 6708–6717. 115 indexed citations
18.
Tassabehji, May, Zhi Fang, Emma Hilton, et al.. (2008). Mutations in GDF6 are associated with vertebral segmentation defects in Klippel-Feil syndrome. Human Mutation. 29(8). 1017–1027. 148 indexed citations
19.
Mhaidat, Nizar M., Rick F. Thorne, Charles E. de Bock, Xu Dong Zhang, & Peter Hersey. (2007). Melanoma cell sensitivity to Docetaxel‐induced apoptosis is determined by class III β‐tubulin levels. FEBS Letters. 582(2). 267–272. 24 indexed citations
20.
Bock, Charles E. de & Yao Wang. (2003). Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer. Medicinal Research Reviews. 24(1). 13–39. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven Goossens Breakdown of academic impact, for papers by Rodrigo Jácamo Breakdown of academic impact, for papers by Diana Bellavia Breakdown of academic impact, for papers by Jesús Pérez‐Losada Breakdown of academic impact, for papers by Juan Carlos Rodríguez‐Manzaneque Breakdown of academic impact, for papers by Deniz Toksoz Breakdown of academic impact, for papers by Shravan K. Chintala Breakdown of academic impact, for papers by Misao Ohki Breakdown of academic impact, for papers by Luke B. Hesson Breakdown of academic impact, for papers by D. Wade Clapp
Rankless by CCL
2026